3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In carcinomas, the nature of CD40 ligand shapes the outcome of CD40 ligation. To date, the consequences of membrane-bound CD40L (mCD40L) on its immune-stimulatory function are unknown. Here, we examined the impact of mCD40L versus soluble CD40L (sCD40L) on T24 bladder carcinoma gene expression profiling. Of 410 differentially expressed genes, 286 were upregulated and 124 downregulated by mCD40L versus sCD40L. Gene ontology enrichment analysis revealed immune-stimulatory function as the most significant enriched biological process affected by upregulated transcripts, while those downregulated were critical for cell growth and division. Furthermore, immature dendritic cells (iDC) responded to mCD40L with enhanced maturation and activation over sCD40L evidenced by higher expression levels of CD83, CD86, HLA-DR and CD54, increased secretion of IL12 and IL10 and higher tumour-antigen (TA) uptake capacity. Furthermore, autologus CD3+ T cells responded to TA-loaded mCD40L-activated DC with increased proliferation and cytotoxic response (CD107a and IFN-γ-producing CD3+ CD8+ T cells) to the tumour-loaded autologous PBMCs compared to sCD40L. Thus, these data indicate that mCD40L enhances the immunostimulatory capacity over sCD40L. Furthermore, the ability of mCD40L to also directly induce cell death in CD40-expressing carcinomas, subsequently releasing tumour-specific antigens into the tumour microenvironment highlights the potential for mCD40L as a multi-faceted anti-cancer immunotherapeutic.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

          Although in vivo priming of CD8+ cytotoxic T lymphocytes (CTLs) generally requires the participation of CD4+ T-helper lymphocytes, the nature of the 'help' provided to CTLs is unknown. One widely held view is that help for CTLs is mediated by cytokines produced by T-helper cells activated in proximity to the CTL precursor at the surface of an antigen-presenting cell (APC). An alternative theory is that, rather than being directly supplied to the CTL by the helper cell, help is delivered through activation of the APC, which can then prime the CTL directly. CD40 and its ligand, CD40L, may activate the APC to allow CTL priming. CD40L is expressed on the surface of activated CD4+ T-helper cells and is involved in their activation and in the development of their effector functions. Ligation of CD40 on the surface of APCs such as dendritic cells, macrophages and B cells greatly increases their antigen-presentation and co-stimulatory capacity. Here we report that signalling through CD40 can replace CD4+ T-helper cells in priming of helper-dependent CD8+ CTL responses. Blockade of CD40L inhibits CTL priming; this inhibition is overcome by signalling through CD40. CD40-CD40L interactions are therefore vital in the delivery of T-cell help for CTL priming.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

            To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both. This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum. We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the long-standing paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

              We investigated the possibility that T helper cells might enhance the stimulatory function of dendritic cells (DCs). We found that ligation of CD40 by CD40L triggers the production of extremely high levels of bioactive IL-12. Other stimuli such as microbial agents, TNF-alpha or LPS are much less effective or not at all. In addition, CD40L is the most potent stimulus in upregulating the expression of ICAM-1, CD80, and CD86 molecules on DCs. These effects of CD40 ligation result in an increased capacity of DCs to trigger proliferative responses and IFN- gamma production by T cells. These findings reveal a new role for CD40- CD40L interaction in regulating DC function and are relevant to design therapeutic strategies using cultured DCs.
                Bookmark

                Author and article information

                Contributors
                elmetwaa@liverpool.ac.uk
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                15 January 2020
                15 January 2020
                2020
                : 10
                : 342
                Affiliations
                [1 ]ISNI 0000 0004 1936 8470, GRID grid.10025.36, Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, , University of Liverpool, ; 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE UK
                [2 ]ISNI 0000 0001 2151 8157, GRID grid.419725.c, Present Address: National Research Centre, ; 12662 Dokki, Giza Egypt
                [3 ]ISNI 0000 0004 1936 7486, GRID grid.6572.6, Institute of Immunology and Immunotherapy, , University of Birmingham, ; Birmingham, B15 2TT UK
                [4 ]ISNI 0000 0000 8700 0572, GRID grid.8250.f, Department of Biosciences, , Durham University, ; Durham, DH1 3LE UK
                [5 ]ISNI 0000 0004 1936 9262, GRID grid.11835.3e, Sheffield Academic Unit of Oncology Department of Oncology and Metabolism Medical School, , University of Sheffield, ; Sheffield, S10 2 RX UK
                [6 ]ISNI 0000 0000 8809 1613, GRID grid.7372.1, Warwick Medical School, , University of Warwick, ; Coventry, CV4 7AL UK
                [7 ]ISNI 0000 0004 0614 6369, GRID grid.418624.d, Clatterbridge Cancer Centre NHS Foundation Trust, ; Clatterbridge Road, Bebington, Wirral, CH63 4JY UK
                Article
                57293
                10.1038/s41598-019-57293-y
                6962220
                31941968
                46e36f38-ba5b-4e49-8ff8-cc760ea4810c
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 September 2019
                : 24 December 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100000357, North West Cancer Research Fund (NWCR);
                Funded by: FundRef https://doi.org/10.13039/501100000289, Cancer Research UK (CRUK);
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                translational immunology,targeted therapies
                Uncategorized
                translational immunology, targeted therapies

                Comments

                Comment on this article